United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$355.59 USD
+2.59 (0.73%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $355.80 +0.21 (0.06%) 6:42 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$355.59 USD
+2.59 (0.73%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $355.80 +0.21 (0.06%) 6:42 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
by Zacks Equity Research
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal third-quarter revenues.
Implied Volatility Surging for United Therapeutics (UTHR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to United Therapeutics (UTHR) stock based on the movements in the options market lately.
Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
If You Invested $1000 in United Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
UTHR vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
5 High ROE Stocks to Buy as Low Inflation Fuels Rate Cut Hopes
by Supriyo Bose
United Therapeutics (UTHR), ABB (ABBNY), Lockheed Martin (LMT), MPLX (MPLX) and Banco de Chile (BCH) are some of the stocks with high ROE to profit from as easing inflationary pressures ignite rate cut hopes.
Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
United Therapeutics (UTHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
What Makes United Therapeutics (UTHR) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
UTHR or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
United Therapeutics Corporation (UTHR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
United Therapeutics (UTHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics (UTHR) Completes Enrolment in IPF Study
by Zacks Equity Research
United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
by Zacks Equity Research
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.